Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/03/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 of the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.7 pts more than Nifty Microcap 250 and 5.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kabra Drugs Ltd has informed BSE that its Board of Directors will meet on Saturday, March 7, 2026, at the company's Corporate Office in Chennai. The main items on the agenda are: (1) a proposal to change the company's name, which will require shareholder and Ministry of Corporate Affairs (MCA) approval, and (2) discussion and approval of a strategic expansion of business operations into Indonesia and Canada. The meeting may also take up any other business matter with the Chairman's permission. The intimation has been filed under Regulation 29 of the SEBI Listing Obligations and Disclosure Requirements.
Shareholders should watch for the name-change outcome, which may signal a rebranding tied to the company's pivot toward international markets. The proposed expansion into Indonesia and Canada hints at growth ambitions, though no financial details, capital outlay, or timelines have been disclosed yet, so the stock is unlikely to move sharply until specifics emerge.